A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease. Extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses.